Filtered By:
Condition: Hemorrhagic Stroke
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 575 results found since Jan 2013.

Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor
AbstractApproximately 1 in 3 –4 patients presenting with an ischemic stroke will also have atrial fibrillation (AF), and AF-related strokes can be effectively prevented using oral anticoagulant therapy (OAC), either with well-controlled vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs). In a ddition, OAC use (both VKAs and NOACs) is associated with a 26% reduction in all-cause mortality (VKAs) or an additional 10% mortality reduction with NOACs relative to VKAs. The decision to use OAC in individual AF patient is based on the estimated balance of the benefit from ischemic stroke reducti...
Source: Advances in Therapy - December 7, 2016 Category: Drugs & Pharmacology Source Type: research

Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania
ConclusionsThe 90-day mortality of stroke presenting at MNH is 50%, much higher than in higher income settings. Although severe stroke presentations are a major factor, efforts to improve the quality of care and prevent complications of stroke are urgently needed. Acute stroke interventions with low number needed to treat represent challenging long-term goals.
Source: International Journal for Quality in Health Care - August 28, 2018 Category: International Medicine & Public Health Source Type: research

Comparison of aspirin and P2Y12 inhibitors for secondary prevention of ischaemic stroke: A systematic review and meta-analysis
CONCLUSION: This meta-analysis suggests that P2Y12 inhibitors are more effective than aspirin in preventing recurrent ischaemic stroke among ischaemic stroke patients despite the absence of any effect on a new ischaemic or haemorrhagic stroke, a new clinical vascular event, all-cause death, and major or minor bleeding events.PMID:35619249 | DOI:10.2174/2772432817666220526162144
Source: Pharmacological Reviews - May 27, 2022 Category: Drugs & Pharmacology Authors: Kaili Zhang Yongle Wang Tingting Liu Xiaoyuan Niu Source Type: research

Antiplatelet therapy for preventing stroke in patients with chronic kidney disease.
Abstract Chronic kidney disease (CKD), defined as reduced glomerular filtration rate and/or proteinuria, is a serious worldwide health problem. The incidence and prevalence of CKD are increasing with age, and patients with CKD are a population at very high risk for developing stroke. CKD may increase the risk for incident stroke independent of conventional stroke risk factors. A common pathological process including anemia, homocysteine, nitric oxide, oxidative stress, inflammation, and conditions promoting coagulation may be related to the development of stroke in the course of CKD. CKD can also serve as a marker...
Source: Contributions to Nephrology - May 26, 2013 Category: Urology & Nephrology Authors: Kim SJ, Bang OY Tags: Contrib Nephrol Source Type: research

New Watchman study reports positive data
New data from a study of Boston Scientific (NYSE:BSX)’s Watchman left atrial appendage closure device reports positive results in a study comparing it to warfarin, an anticoagulant drug treatment, in patients with nonvalvular atrial fibrillation. The 2,406-patient study, published in the Journal of the American College of Cardiology, reported a lower rate of hemorrhagic strokes, unexplained and cardiovascular death and non-procedural bleeding when compared to warfarin. “I think the fact that we now actually have some good scientific data in the field is terribly important, it has been lacking. But I think we...
Source: Mass Device - June 16, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Boston Scientific Stroke Source Type: news

Acute Ischemic Stroke as a Presenting Feature of Multiple Myeloma (P3.279)
Conclusions:Stroke is a leading and preventable cause of disability in the US adult population. The majority of strokes are due to atherosclerotic vascular or cardioembolic disease. Understanding the diagnostic work up of stroke and recognizing rare etiologies like MM is important for stroke prevention. This brings to light the importance of recognizing stroke as an initial presenting feature of multiple myeloma and of multiple myeloma as an important treatable etiology of stroke.Disclosure: Dr. Chung has nothing to disclose. Dr. Ramamoorthy has nothing to disclose. Dr. Kar has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Chung, S., Ramamoorthy, R., Kar, J. Tags: Cerebrovascular Disease Case Reports II Source Type: research

Case-crossover analysis of short-term particulate matter exposures and stroke in the health professionals follow-up study.
CONCLUSIONS: Our study provides evidence that ambient PM10 may be associated with higher risk of ischemic stroke and highlights that ischemic and hemorrhagic strokes are heterogeneous outcomes that should be treated as such in analyses related to air pollution. PMID: 30641259 [PubMed - as supplied by publisher]
Source: Environment International - January 11, 2019 Category: Environmental Health Authors: Fisher JA, Puett RC, Laden F, Wellenius GA, Sapkota A, Liao D, Yanosky JD, Carter-Pokras O, He X, Hart JE Tags: Environ Int Source Type: research

The efficacy and safety of Hirudin plus Aspirin versus Warfarin in the secondary prevention of Cardioembolic Stroke due to Nonvalvular Atrial Fibrillation: A multicenter prospective cohort study.
Conclusion: Significant difference in efficacy was not detected between warfarin group and hirudin plus aspirin group. Compared with warfarin, hirudin plus aspirin therapy had lower safety risk in the secondary prevention of cardioembolic stroke due to NVAF. PMID: 33526977 [PubMed - in process]
Source: International Journal of Medical Sciences - February 3, 2021 Category: Biomedical Science Tags: Int J Med Sci Source Type: research

Oral antiplatelet therapy for acute ischaemic stroke
CONCLUSIONS: Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, significantly decreased death and dependency, and reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved.PMID:35028933 | DOI:10.1002/14651858.CD000029.pub4
Source: Cochrane Database of Systematic Reviews - January 14, 2022 Category: General Medicine Authors: Jatinder S Minhas Tamara Chithiramohan Xia Wang Sam C Barnes Rebecca H Clough Meeriam Kadicheeni Lucy C Beishon Thompson Robinson Source Type: research

Effect of Low-Dose Aspirin on Functional Outcome From Cerebral Vascular Events in Women Original Contributions
Conclusions— Results from this large randomized clinical trial provide evidence that 100 mg of aspirin every other day may reduce the risk of ischemic cerebral vascular events but does not have differential effects on functional outcomes from stroke.
Source: Stroke - January 18, 2013 Category: Neurology Authors: Rist, P. M., Buring, J. E., Kase, C. S., Kurth, T. Tags: Acute Cerebral Infarction, Epidemiology Original Contributions Source Type: research